Vedolizumab as a first-line biologic for Crohn’s?
Trial shows patients with severe disease can achieve remission
About one patient in eight experiences endoscopic remission of Crohn’s disease after completing 26 weeks of treatment with the gut-selective monoclonal antibody vedolizumab, a study shows.
In the phase 3b open-label VERSIFY study, sponsored by Takeda Pharmaceuticals, the biologic was tested in 101 patients with moderately-to-severely active Crohn’s disease.
Twelve patients achieved the primary endpoint of endoscopic remission (defined as a Simple Endoscopic Score for Crohn’s of four or less) at week 26.
“(These) data are in line with other biologics,” said lead author Dr Silvio Danese, from Humanitas University in Milan, Italy.
